Accession Number : AD1032817

Title :   Treatment of Nueropathic Pain after SCI with a Catalytic Oxidoreductant

Descriptive Note : Technical Report,30 Sep 2015,29 Sep 2016

Corporate Author : University of Alabama at Birmingham Birmingham United States

Personal Author(s) : Floyd,Candace L

Full Text :

Report Date : 01 Oct 2016

Pagination or Media Count : 75

Abstract : The on-going research is to test the central hypothesis that post-SCI administration of the catalytic oxidoreductant BuOE will inhibit neuropathic pain after SCI. The research in years1-3 focused on the goals of aims 1-3, to test the hypothesis that post-SCI administration of BuOE decreases inflammation and ROS activation in a rat, mouse and porcine model of SCI. The main finding of our work in this year was to evaluate the dose-effect curve of post-SCI administration of BuOE on the outcomes listed above. Our data from on-going experiments indicate that the dose of 0.2mg/kg BuOE was most effective in reducing inflammation and ROS activation acutely post-SCI in rats and mice. On-going experiments will evaluate additional outcome measures and behavioral outcomes in the subsequent year.

Descriptors :   spinal cord , wounds and injuries , therapeutics , liquid chromatography , biological factors , proteins , pain , inflammation , surgical procedures , arteries , blood

Subject Categories : Anatomy and Physiology

Distribution Statement : APPROVED FOR PUBLIC RELEASE